NDA 218037 · Alexion Pharms INC
Voydeya
Danicopan · Oral · Complement Factor D Inhibitor
NovelBreakthrough therapyOrphanCDER novel approval, Mar 29, 2024: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 29, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
26
3 Phase 3, 1 recruiting
FAERS reports
310
242 serious, 20 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA VOYDEYA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Neisseria meningitidis , Streptococcus pneumoniae , and Haemophilus influenzae type B [ see Warnings and Precautions (5.1) ]. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for encapsulated bacteria specifically, Neisseria meningitidis and Streptococcus pneumoniae at least 2 weeks prior to the first dose of VOYDEYA, unless the risks of delaying therapy with VOYDEYA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices...
What it is approved for
From the label in effect May 12, 2026.
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.
Mechanism: Danicopan binds reversibly to complement Factor D and selectively inhibits the alternative complement pathway. Danicopan prevents the cleavage of complement Factor B into the Ba and Bb fragments which are required for the formation of the alternative pathway (AP) complement component C3 convertase (C3bBb), the generation of downstream effectors including C3 fragment opsonization, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the terminal membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3 fragment...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 2024 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLetterReview
2 products under this application
- VOYDEYA · DANICOPAN 100MG · TABLET, ORAL · Prescription
- VOYDEYA · DANICOPAN 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Danicopan" as an intervention, any sponsor and status, largest first.
- A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationPivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05019521 · 365 participants · Start Aug 23, 2021 · Primary completion Jul 5, 2024
Drug: Danicopan; Placebo · For: Geographic Atrophy
Sites: Phoenix, Arizona; Beverly Hills, California; Encino, California · 128 sites in all
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04988035 · 201 participants · Start Aug 3, 2021 · Primary completion Apr 23, 2022
Drug: Danicopan; Remdesivir · For: COVID-19
Sites: Birmingham, Alabama; Bakersfield, California; Fresno, California · 39 sites in all
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)Pivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04469465 · 86 participants · Start Dec 16, 2020 · Primary completion Jun 29, 2022
Drug: Danicopan; Placebo and 1 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Los Angeles, California; Weston, Florida; Chicago, Illinois · 62 sites in all
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05389449 · 80 participants · Start Oct 28, 2022 · Primary completion Aug 24, 2026
Drug: Danicopan · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland · 45 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05109390 · 72 participants · Start Jul 27, 2018 · Primary completion Oct 17, 2018
Drug: Danicopan; Cyclosporine and 4 more · For: Healthy
Sites: Tempe, Arizona
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04709094 · 52 participants · Start Jul 28, 2019 · Primary completion Oct 14, 2019
Drug: Danicopan; Warfarin and 2 more · For: Healthy
Sites: Tempe, Arizona
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04889690 · 45 participants · Start May 21, 2016 · Primary completion Jan 11, 2017
Drug: Danicopan; Placebo · For: Healthy
Sites: Auckland, New Zealand
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04889677 · 44 participants · Start Feb 4, 2016 · Primary completion Jun 21, 2016
Drug: Danicopan; Placebo · For: Healthy
Sites: Auckland, New Zealand
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemoglobin decreased36
- haemolysis28
- fatigue24
- breakthrough haemolysis23
- extravascular haemolysis20
- drug ineffective17
- off label use17
- pneumonia17
- anaemia16
- headache14
- diarrhoea13
- covid-1912
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 75 |
| 2025 | 122 |
| 2026 | 111 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Voydeya (Danicopan)
2024 spending
$499K
Beneficiaries
32
120 claims
Per beneficiary
$15,603
$23.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $499,298 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, et al. · Lancet Haematol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Nester C, Appel GB, Bomback AS, et al. · Am J Nephrol 2022 · Randomized Controlled Trial, Clinical Trial, Phase II
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.
Kulasekararaj A, Griffin M, Piatek C, et al. · Blood 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. · Blood 2021 · Clinical Trial, Phase II, Multicenter Study
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos SD, Trachtman H, Appel GB, et al. · Am J Nephrol 2022 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis.
Muvaffak E, Mokresh ME, Varda A, et al. · Expert Rev Hematol 2024 · Systematic Review, Meta-Analysis
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.